- Home
- NTRB vs ALGS Comparison
NTRB vs ALGS Comparison
Compare NTRB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | ALGS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 34.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NTRB | ALGS |
|---|---|---|
| Price | $5.34 | $6.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 26.0K | ★ 124.6K |
| Earning Date | 05-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | $2,036,651.00 | ★ $2,186,000.00 |
| Revenue This Year | $30.17 | $32.20 |
| Revenue Next Year | $3,394.36 | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $3.98 |
| 52 Week High | $8.63 | $13.69 |
Technical Indicators
Market Signals| Indicator | NTRB | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 70.25 | 49.37 |
| Support Level | $4.14 | $4.80 |
| Resistance Level | $4.98 | $6.91 |
| Average True Range (ATR) | 0.41 | 0.57 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 68.37 | 30.81 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.